Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Selexipag

If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

DRUG

Riociguat

If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.

DEVICE

CardioMEMS pulmonary artery pressure monitor

Implantation and remote monitoring established with patient initiated daily readings

DEVICE

Confirm Rx

Implantation and remote monitoring established with automated daily readings / downloads

Trial Locations (1)

S10 2JF

RECRUITING

Sheffield Teaching Hospitals NHS FT, Sheffield

All Listed Sponsors
collaborator

University of Glasgow

OTHER

collaborator

University of Sheffield

OTHER

collaborator

University of Newcastle Upon-Tyne

OTHER

collaborator

University of Cambridge

OTHER

lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER